Enanta Pharmaceuticals (NASDAQ:ENTA) Announces Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.09), Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.

Enanta Pharmaceuticals Trading Down 2.9%

Shares of Enanta Pharmaceuticals stock traded down $0.32 during trading hours on Monday, hitting $10.67. 173,236 shares of the company were exchanged, compared to its average volume of 214,537. The business has a 50-day moving average of $11.95 and a 200-day moving average of $13.08. Enanta Pharmaceuticals has a 1 year low of $10.05 and a 1 year high of $17.15. The stock has a market capitalization of $310.76 million, a price-to-earnings ratio of -4.43 and a beta of 0.75.

Analyst Upgrades and Downgrades

ENTA has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Thursday, October 15th. Wall Street Zen downgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, October 11th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $20.00.

Get Our Latest Stock Report on ENTA

About Enanta Pharmaceuticals

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

Read More

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.